Navigation Links
Trials in Medical Technology

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program

FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

VIENNA, July 15 /PRNewswire-USNewswire/ -- This week, more than 3,000 leading scientists convened to report and discuss the latest advances in research on treatments, risk factors, diagnosis and causes for the health epidemic of the 21st century -- Alzheimer's disease -- at the Alzheimer's As...

Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline

VIENNA, Austria, July 12 /PRNewswire/ -- Results from two large studies using DHA, an omega 3 fatty acid, were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna. (Logo: http://www.newscom.com/cgi-bi...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...

New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases

Bill would remove financial penalties for participating in research studies BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for government health...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patie...

Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun

SAN FRANCISCO, May 6 /PRNewswire-FirstCall/ -- Medizone (Pink Sheets: MZEI) is pleased to announce the commencement of the first in a series of trials designed to confirm that the Medizone AsepticSure(TM) Hospital Sterilization System can rapidly eliminate hospital-based bacterial pathogens known ...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Phase 2b clinical trials will commence this week on 30 Type 2 Diabetic volunteers. The study is intended to evaluate the safety, t...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials - - Company to Hold Investor Event on Sunday, May 31 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today ann...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session

SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...

Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.

Company Expands Overseas TBI Trial COSTA MESA, Calif., March 19 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received a letter from the FDA that outlines what the agency termed a "path forward" as a basis to resume clin...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates o...

Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it will delay further partnership discussions regarding R788 until after results from the Phase 2b clinical trials of R788 are available. The company expects that ...

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its current financial status, the Board of Directors and management have determined that it is in the best int...

Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation

RESEARCH TRIANGLE PARK, N.C., Jan. 26 /PRNewswire/ -- Mardil Inc., a cardiac device company with novel technology for treating mitral valve regurgitation, has successfully advanced its device to first-in-human testing, a milestone achievement for the 2-year-old company. The first patient was...

Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia

PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced completion of enrollment in the second of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. "Completion of enrollment in thi...

ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 stu...

Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

SKOKIE, Ill., Dec. 2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints. HZT-501, a novel, proprietary fixed-dose combinati...

GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America

ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of its Phase 2a Human Va...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, whi...

Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management

Renowned cancer research center enters into a Technology Transition agreement with OmniComm to gain more control over the management of their clinical trials FT. LAUDERDALE, Fla., Nov. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...

Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository

JERUSALEM, October 23 /PRNewswire-FirstCall/ -- - An Insulin Suppository Represents an Important Development in the Treatment of Diabetes as it Provides a Painless Alternative for Effective Insulin Delivery Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; http://www.oramed.com ), a developer...

First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20

Community Leaders/Patients Encouraged to Discuss Challenges; Offer Solutions NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- On the heels of a major report revealing that the vast majority of Americans -- and especially women, older people and racial and ethnic minorities -- are either under-re...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issu...

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 - EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a meeting with the U.S. Food ...

Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months

LYON, France, Oct. 8 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL ) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin(R) adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based ...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008

Design Concept of Other Product - Company's Bioabsorbable Stent - Also Slated for Presentation at Symposium HONG KONG, Oct. 6 /PRNewswire/ -- Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, will be presented next week at t...

Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

Study to Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule, on Type 1 Diabetics JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announ...

Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT

New Data from Landmark UPLIFT Trial Further Supports Spiriva's Safety Profile RIDGEFIELD, Conn. and NEW YORK, Sept. 23 /PRNewswire/ -- Boehringer Ingelheim and Pfizer Inc have released a new analysis of 30 rigorously controlled clinical trials, including UPLIFT, confirming the long term safe...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending do...

Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

Company to Discuss Phase 3 Plans with FDA PRINCETON, N.J., Sept. 3 /PRNewswire/ -- Agile Therapeutics, Inc., announced today that it successfully completed two key clinical trials in the development of the company's new, innovative low-dose, once-weekly, contraceptive patch, whi...

Clinical Trials Bootcamp Announces Inaugural Meeting

WEST PALM BEACH, Fla., Aug. 14 /PRNewswire/ -- The Clinical Trials Bootcamp announces its inaugural meeting aimed at educating physicians, clinical coordinators, clinical research staff and other participants in clinical trial. It will be held in Boca Raton at the Boca Resort from May 14-17th,...

Aon eSolutions Launches Clinical Trials Module

Provides risk managers with comprehensive overview of clinical trials, including exposure and required coverage CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- Aon eSolutions, the client technology arm of Aon Corporation (NYSE: AOC ) and the leading provider of global risk and insu...
Other Tags
(Date:8/1/2014)... elements are a key component of phloem, the conductive ... range of signalling molecules. Elongated cylindrical cells are capped ... end-to-end to form sieve tubes which in turn form ... "Sieve elements are very special cells which play an ... little has been known about their differentiation," says Professor ...
(Date:8/1/2014)... Fla. , Aug. 1, 2014  LiveScan Service Provider Binary Biometrics ... owner/operator team. As a result, Binary Biometrics will improve its mobile service capabilities ... Volusia County and service several new cities such as, ... , DeLand , Deltona , ... Helen , New Smyrna Beach , Oak ...
(Date:7/31/2014)... supported by the National Science Foundation (NSF), counters ... accelerates atmospheric warming, indicating instead that certain Arctic ... into the atmosphere. , The study, published ... focuses on thermokarst lakes, which occur as permafrost ... melted fresh water, converting what was previously frozen ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3Certain Arctic lakes store more greenhouse gases than they release 2
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... Cincinnati, Ohio (PRWEB) August 01, 2014 ... in-home care for seniors, is honored to be recognized as ... prestigious award is given to home care providers who rank ... satisfaction categories, based on monthly satisfaction interviews conducted by Home ... recognize the leading home care businesses, the best of the ...
(Date:8/1/2014)... In recent years, minimally invasive aesthetic injectable procedures have ... women are seeking age-defying treatments. As Botulinum toxin ... a growing number of nonaesthetic health professionals have emerged ... Small, MD and Henry M. Spinelli, MD from the ... and Kathleen M. Kelly, MD from Columbia University in ...
(Date:8/1/2014)... 2014 CapsCanada, a leading provider ... a new K-CAPS® (HPMC capsules) manufacturing facility in ... plans last year while experiencing growing global demand ... Manager, “KCAPS® are currently sold in more than ... “Compared to other HPMC capsules, K-CAPS® have exceptional ...
(Date:8/1/2014)... MA (PRWEB) August 01, 2014 For ... even when memory is still within the normal range, ... warning signs of future decline. This merits a closer ... in the August 2014 Harvard Men's Health Watch ... that if they forget where their keys are they ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
Other Contents